Established in 1981, Infosys is a NYSE listed global consulting and IT services company with more than 242k employees. It has grown to become a US$ 12.78 billion (FY20 revenues) company with a market capitalization of approximately US$ 35 billion.
Infosys is known for its innovations and funding start-ups and most recently it has launched explicit software for the pharma sector. This announcement has come in times where the whole world is heavily dependent on the health sector due to the Covid-19 outbreak.
Infosys said in a statement, “The modular solution uses advanced analytics to manage individual patient treatment lifecycle from enrollment and scheduling to post medical treatments and can notably reduce patient treatment lifecycle, it added. The solution uses Internet of Things (IoT) and blockchain to manage critical cold chains and outcome-based invoicing. The solution incorporates into an existing business process with minimal disruptions, reducing implementation time, thus enabling quicker product launches for pharma companies.”
With an extremely positive outlook, Infosys SVP and Global Head of Life Sciences Subhro Mallik contended, “With rapid growth in digital technologies and advances in biology, the personalised medicine market is projected to grow significantly, and we see a huge opportunity in this space. Digital technologies can help pharma companies accelerate their time to market and provide better patient experiences.”
On 30th June, 2020 11:35 am; The stock was trading at a price of Rs. 732.25 per share on the National Stock Exchange (NSE).
Infosys today announced the launch of an all-new, Personalized Medicine solution for the #pharmaceutical industry. The solution leverages SAP S/4HANA, the SAP C/4HANA suite, the SAP Analytics Cloud solution, and SCI platform. https://t.co/5OEuAPmSUW #InfyNews pic.twitter.com/i4iXdQzPmf
— Infosys (@Infosys) June 29, 2020
